Cingulate Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CING research report →
About the company
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
- CEO
- Shane J. Schaffer
- IPO
- 2021
- Employees
- 13
- HQ
- Kansas City, KS, US
Price Chart
- Market Cap
- $30.16M
- P/E
- -1.07
- P/S
- 0.00
- P/B
- 1.55
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -365.16%
- ROIC
- -91.87%
- Revenue
- $0 · 0.00%
- Net Income
- $-22,449,911 · -35.57%
- EPS
- $-4.13 · 59.51%
- Op Income
- $-19,938,108
- FCF YoY
- 6.73%
- 52W High
- $11.89
- 52W Low
- $3.16
- 50D MA
- $4.87
- 200D MA
- $5.01
- Beta
- -0.92
- Avg Volume
- 560.21K
Get TickerSpark's AI analysis on CING
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Silva Raul R. | other | 3,885 |
| Feb 13, 26 | Hargroves Thomas Jeffrey | buy | 97,276 |
| Feb 13, 26 | Hargroves Thomas Jeffrey | buy | 77,821 |
| Mar 9, 26 | Hargroves Thomas Jeffrey | other | 15,000 |
| Feb 13, 26 | Hargroves Thomas Jeffrey | other | 0 |
| Dec 10, 21 | Hargroves Thomas Jeffrey | other | 35 |
| Mar 31, 26 | Silva Raul R. | other | 3,422 |
| Mar 9, 26 | Silva Raul R. | other | 4,526 |
| Mar 9, 26 | Silva Raul R. | other | 1,828 |
| Mar 9, 26 | Schaffer Shane J. | other | 6,862 |
Our CING coverage
Recent articles, reports, and earnings notes.
No research on CING yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CING report →Similar companies
Peers in the same neighborhood.